otezla-header-logo
  • GET STARTED
  • DISEASE AREAS
    • PSORIASIS
      • ACTUAL PATIENT RESULTS
      • EFFICACY PROFILE
      • SAFETY PROFILE
      • OUR EXPERIENCE
    • PSORIATIC ARTHRITIS
      • EFFICACY PROFILE
      • SAFETY PROFILE
      • OUR EXPERIENCE
    • NEW: BEHÇET’S DISEASE
      • EFFICACY PROFILE
      • SAFETY PROFILE
  • PHARMACOLOGY
  • ez Start PSP
  • SAFETY INFORMATION
  • CONTACT US
  • EN FR
  • MY PROFILE
  • LOG OUT

OTEZLA® is available on the RxHelpTM ONE program. The program covers up to the difference in cost between OTEZLA® and its generic alternative(s)*

* Available in select provinces only. Refers to drug acquisition cost and reasonable markup. Dispensing fees not covered. Program can end at the manufacturer’s discretion.

Enter site to learn more

an oral tablet
for the treatment
of adults with:1

home-apr-image
plaque-psoriasis

moderate-to-severe plaque psoriasis

Learn more
psoriatic-arthritis

active
psoriatic arthritis

Learn more
behcets-disease

oral ulcers associated with Behçet’s disease

Learn more
globe

>1 MILLION patients have been treated with OTEZLA globally to date, combined across all three indications.2*

* Clinical significance has not been established.

OTEZLA (apremilast) is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

OTEZLA, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response, intolerance, or contraindication to a prior disease-modifying anti-rheumatic drug (DMARD).

OTEZLA is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s disease who are candidates for systemic therapy.

Consult the Product Monograph or click here for important information on:

  • Contraindications in pregnancy and women who are breastfeeding
  • Relevant warnings and precautions regarding history of tachyarrhythmia or conditions worsened by increases in heart rate; weight loss; diarrhea, nausea, and vomiting; hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose–galactose malabsorption; severe immunological diseases, severe acute infectious diseases, or patients treated with immunosuppressive medicinal products; headache and migraine; history of depression and/or suicidal thoughts or behaviour; severe renal impairment
  • Conditions of clinical use, adverse reactions, drug interactions, dosing instructions, and dosage adjustments in patients with severe renal impairment

The Product Monograph is also available by calling us at 1-866-502-6436.

Continue
patient-support-program-logo.svg

Contact the ez Start Patient Support Program:


1-844-ez-Start (1-844-397-8278)
Monday–Friday, 8:00 AM–8:00 PM ET
  • Privacy Policy
  • Terms of use
  • Cookie Settings
amgen-logo

OTEZLA® is a registered trademark of Amgen GmbH.

ez Start™ is a trademark owned or licensed by Amgen Inc.,
its subsidiaries or affiliates.

© 2025 Amgen Canada Inc. All rights reserved.

innovative-paab

CAN-407-1122-80010-E